Horizon Makes The Case For An Ambitious $10Bn Sales Goal
The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.
You may also be interested in...
A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sj
A clinical trial confimred Krystexxa in combination with methotrexate increased response rates in patients with uncontrolled gout.
Horizon will gain the commercial product Uplizna and three pipeline products for rare diseases, where it can build on its success with Tepezza. Horizon is also interested in Viela's R&D team.